Methods to mediate polyketide synthase module effectiveness
    91.
    发明授权
    Methods to mediate polyketide synthase module effectiveness 有权
    介导聚酮化合物合酶模块有效性的方法

    公开(公告)号:US06753173B1

    公开(公告)日:2004-06-22

    申请号:US09500747

    申请日:2000-02-09

    IPC分类号: C12N900

    CPC分类号: C12N9/93 C12P19/62

    摘要: Linking sequences that modulate cross-talk between modules of Type I polyketide synthases have been identified and methods for their use are described. Arbitrarily chosen modules can be mixed and matched by supplying the appropriate linkers to facilitate transfer of a growing polyketide chain between modules. Employing these techniques, new polyketide end products may be obtained.

    摘要翻译: 已经鉴定了调节I型聚酮化合物合酶的模块之间的串扰的连接序列,并描述了其使用方法。 可以通过提供适当的接头来混合和匹配任意选择的模块,以促进模块之间生长的聚酮化合物链的转移。 采用这些技术,可以获得新的聚酮化合物终产物。

    Biomarker to Measure Drug Efficacy in Enteropathic Disease
    97.
    发明申请
    Biomarker to Measure Drug Efficacy in Enteropathic Disease 审中-公开
    生物标志物测定肠病中的药效

    公开(公告)号:US20130065255A1

    公开(公告)日:2013-03-14

    申请号:US13604329

    申请日:2012-09-05

    IPC分类号: G01N27/62 G01N33/566

    摘要: The diagnosis of a patient with an enteropathic disease or the response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, serum breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

    摘要翻译: 通过检测患者代谢口服CYP3A底物的能力来评估患有肠病的患者或具有肠病的患者对治疗特别是临床试验环境中的候选治疗的反应的诊断。 可以以各种方式监测CYP3A代谢。 方便地,在口服给药后的一段时间内,在患者样品中检测到CYP3A底物的代谢物的出现,例如, 在尿液,血浆,血清呼吸,唾液等中。CYP3A底物任选地标记,例如。 与同位素,荧光等标签。